Nutrigenetics-based intervention approach for adults with non-alcoholic fatty liver disease (NAFLD): study protocol for a randomised controlled feasibility trial

Laura Haigh,1,2 Stuart McPherson,1,2 John C Mathers,3 Quentin M Anstee1,2

ABSTRACT

Introduction  Lifestyle interventions targeting weight loss and improved dietary patterns are the recommended treatment for non-alcoholic fatty liver disease (NAFLD). However, the effectiveness of current established diet therapies is suboptimal. The patatin-like phospholipase domain containing 3 (PNPLA3) gene modifies disease outcome and hepatic lipid handling, but the role of PNPLA3 variants in modulating responsiveness to different diet therapies is unknown.

Methods and analysis  This project aims to assess the feasibility of conducting a genotype-driven randomised controlled trial (RCT) investigating the differential response to a Mediterranean diet (MD) intervention of NAFLD patients according to genotype for the rs738409 (I148M) variant of PNPLA3. A single-centre randomised controlled feasibility trial will be undertaken. We will recruit 60 adults with NAFLD from a tertiary hepatology centre in England. In a cross-over design, participants will undertake Diet 1 (MD) and Diet 2 (control) for 4 weeks, in random order (1:1 allocation), separated by a 4-weeks washout period. Participants will complete one-to-one diet and lifestyle consultations at baseline, end of diet phase 1, end of washout and end of diet phase 2. Participants will be advised to maintain baseline levels of physical activity and body weight. The primary outcome is the acceptability and feasibility of the intervention protocol. Secondary outcomes include exploratory assessment of liver fibrosis biomarkers and lipid biomarkers.

Ethics and dissemination  Ethical approval was granted by East of Scotland Research Ethics Service REC 1 (19/ES/0112). Results will be disseminated through peer-reviewed journals and presented at local, national and international meetings and conferences. The findings of this trial will lay the foundation for a future definitive RCT by informing trial design and optimising the intervention diets, instruments and procedures.

Trial registration number  ISRCTN93410321.

INTRODUCTION

Non-alcoholic fatty liver disease (NAFLD) affects 25% of the global population1,2 and is a spectrum spanning steatosis (non-alcoholic fatty liver), through steatosis plus inflammation, hepatocyte damage and progressive fibrosis (non-alcoholic steatohepatitis, NASH), that may potentially develop into cirrhosis and hepatocellular carcinoma.3–5 NAFLD is strongly associated with obesity and cardiometabolic disease.6–8 NAFLD attributed rates of advanced liver disease and transplantation are increasing, but effective pharmacotherapy is unavailable.2,3 A major challenge is the substantial interindividual variation in NAFLD susceptibility, progression and outcome, due partly to gene–environment interactions.2,3 The patatin-like phospholipase domain containing 3 (PNPLA3) rs738409 single nucleotide polymorphism is a common modifier of disease outcome and its impact is amplified by adiposity.7–10 This additive effect poses considerable concern, as patients with
NAFLD tend to consume excess calories as a consequence of poor-quality diets and sedentary lifestyles.\(^{11-13}\)

The PNPLA3 protein has lipase activity and regulates lipid droplets in hepatocytes and hepatic stellate cells.\(^{14}\) Several studies have contributed to understanding of its function in hepatic lipid handling.\(^{15}\) Numerous genome-wide association studies have shown its association with the entire disease spectrum, which has been confirmed in various populations.\(^{8,12,16,17}\) Therefore, among the identified NAFLD-related genes, PNPLA3 has the most potential as a therapeutic target for NAFLD.\(^{10,12}\)

The main treatment recommendations for NAFLD are lifestyle interventions targeting weight loss and improved dietary patterns.\(^{4,5}\) The Mediterranean diet (MD) reduces steatosis, improves liver biochemistry and cardiometabolic dysfunction, with or without weight loss and is the most recommended dietary pattern in NAFLD.\(^{5,18-23}\)

There is strong and consistent evidence that the MD, has beneficial effects on NAFLD-associated conditions such as type 2 diabetes and the metabolic syndrome.\(^{24}\) However, there is suboptimal response to current diet therapies in NAFLD and more effective approaches for enhancing adherence to diet therapies are needed.\(^{11}\)

Personalised nutrition approaches that use information on individual participant characteristics to tailor the dietary intervention may improve the suboptimal response to current diet therapies.\(^{25}\) Differences in gene sequence can alter the activity of encoded proteins and affect the response of individuals to dietary components.\(^{26}\)

Emergent research has shown nutritional regulation of PNPLA3\(^{15,26}\) so that patients with NAFLD carrying the PNPLA3 risk allele might benefit more from weight loss but less from omega-3 supplementation.\(^{26-29}\) Diet lifestyle modification is more effective in decreasing liver steatosis in PNPLA3 I148M carriers than in non-carriers.\(^{29,30}\) Liver fat content is influenced by the interaction between PNPLA3 variants and high carbohydrate intake, specifically sugar.\(^{31}\) A hypocaloric low-carbohydrate diet induced greater hepatic fat reduction in carriers homozygous for the rs738409 G allele in the PNPLA3 gene compared with carriers of the rs738409 C allele, irrespective of weight loss.\(^{32}\) However, the role of PNPLA3 variants in influencing responsiveness to different diet therapies is poorly understood.

This project aims to determine whether it is feasible to conduct a randomised controlled trial (RCT) to investigate the impact of PNPLA3 carriage on responsiveness to MD and NAFLD severity and to provide preliminary data to inform the development of a definitive RCT.

**METHODS AND ANALYSIS**

**Study design and setting**

This trial is a single-centre, randomised controlled feasibility trial. In a cross-over design, participants will be randomised to either Diet 1 (MD) or Diet 2 (control) for 4 weeks, in random order, separated by a 4-week washout period. All study visits will be conducted in the outpatient hepatology services, in The Newcastle upon Tyne Hospitals NHS Foundation Trust (NUTH), UK. An overview of the study design is provided in figure 1.

**Study objectives**

The primary objective is to determine whether the protocol for a future definitive RCT is acceptable and feasible.

We will:

1. Determine the feasibility of recruitment and retention.
2. Determine the acceptability of the diets, instruments and procedures.
3. Evaluate adherence to, and completion of, the diets and procedures.
4. Evaluate implementation fidelity and how practicable it is to deliver the protocol in a clinical setting.
5. Estimate outcome variability.

Secondary objectives include collection of preliminary exploratory data on liver fibrosis biomarkers and lipid biomarkers, to determine if PNPLA3 carriage influences
Box 1  Patient eligibility criteria

**Inclusion criteria**
- 18–80 years old with NAFLD (confirmed on liver biopsy or by clinical diagnosis with imaging evidence of steatosis).
- Weekly alcohol consumption <14 (women)/<21 (men) units in the last 24 months.
- Weight stable (>±5%) for previous 3 months.
- Capacity to provide informed consent.
- Ability to write and converse in English without assistance of an interpreter.

**Exclusion criteria**
- All cancers within 5 years (except squamous cell carcinoma).
- Evidence of coexistent liver disease/presence of secondary causes of NAFLD (except Gilbert’s syndrome).
- Decompensated NASH-cirrhosis (Child Pugh >6).
- Uncontrolled psychiatric disorder (eg, acute psychosis).
- Uncontrolled medical condition (eg, HbA1c >8% or acute coronary event or stroke within 12 months).
- Active eating disorder.
- Active substance misuse.
- Other prescribed dietary regimens, food intolerances and/or food allergies.
- Mediterranean diet score (MEDAS) >8 (high MD consumption).
- Previous weight loss surgery.
- Taking antiobesity medications and/or engaged in structured, multicomponent weight management interventions (specialist, community or commercial providers).
- Insulin use.
- Pregnancy/lactation.

Inclusion and exclusion criteria
Participant eligibility criteria are detailed in box 1. We have chosen minimal exclusions to reflect the target population for a subsequent definitive RCT.

Randomisation and allocation strategy
Eligible participants will be allocated in a 1:1 ratio to receive either Diet 1 or Diet 2 first using computer-generated randomisation. Prerandomisation genotyping for specific genetic variants (PNPLA3 rs738409) will be conducted using blood samples collected at screening. Interim analysis of the genotype distribution among the recruited cohort will be conducted at intervals as recruitment proceeds (eg, after one-third and two-thirds have been randomised); randomisation will then be stratified by PNPLA3 status at baseline to ensure a balanced recruitment for PNPLA3 rs738409 genetic status (wild-type, heterozygote, homozygote).

The major allele frequency for PNPLA3 rs738409 is approximately 0.25 in the UK general population and the minor allele frequency is greater in those with NAFLD. Accordingly, we expect to reach the recruitment target for wild-type cases sooner than for carriers of the genetic variant and so some patients with a specific genotype may not be randomised if sufficient cases of a given genotype are already enrolled. Those discharged from the study will be offered a one-to-one nutrition education and counselling consultation with a dietitian. It will not be possible to blind participants, clinicians or research investigators to which diet each participant is on in each study period.

**Trial procedures**

The trial procedures are outlined in table 1. At an initial screening appointment, demographic, clinical, dietary and lifestyle data will be collected to determine patient eligibility and a blood sample will be taken for PNPLA3 rs738409 genotyping. In addition, at baseline, liver steatosis will be assessed using controlled attenuation parameter measured contemporaneously with liver stiffness by Transient Elastography, Fibroscan.

Enrolled participants will complete one-to-one diet and lifestyle consultations at baseline, end of diet phase 1 (4 weeks), end of washout (8 weeks) and end of diet phase 2 (12 weeks). At each of these timepoints, the following measures will be taken; anthropometry and body composition; blood biochemistry; dietary intake, urine samples and physical activity. The clinical status and medication consumption of participants will be checked at each time-point. Patient-reported outcome data will be captured at the end of each diet phase (4 weeks and 12 weeks).

**Dietary intervention and control treatments**

The experimental Diet 1 is a MD based on the traditional MD pyramid. The MD is characterised by a high quantity of plant-based foods, unrefined cereals, fruit and vegetables, olive oil and nuts; eating white meat, fish and legumes in moderation; restricting red and processed...
meats and sweets; and drinking red wine moderately. The diet was designed to be easy to follow over 4 weeks, informed by research evidence and the findings from our earlier pilot study with patients and the public that explored barriers and facilitators to adoption of a MD intervention. They highlighted the importance of reducing the burden of dietary changes, diet supporters in the household, regular nutritional counselling and preference for face-to-face contacts. These ideas have been incorporated into the final design.

To reduce participant burden and facilitate changes in food environment, some intervention foods will be supplied as prepackaged ready meals (FreshPrepare) and extra virgin olive oil (Filippo Berio). Ten prepackaged ready meals will be home delivered weekly, taken as two main meals per day (lunch and evening meal) for 5 days. The meals can be ordered online, and examples of the available options are detailed in online supplemental appendix table 1. The provision of these intervention foods will assist in standardising food consumption and minimise variability in dietary intake.

To enhance MD adoption, nutrition counselling and education will be provided one-to-one to participants during visits, by a dietitian. This will include advice on the selection and preparation of appropriate meals, snacks and drinks. The consultation incorporates the ‘model and process for nutrition and dietetic practice’, and involves participant discussion. Personalisation of the diet for specific personal and sociocultural preferences will be provided.

A patient information booklet has been designed to explain NAFLD, the principles of MD and how it can be successfully followed. This will be given to participants as evidence-based written material from a credible source. Behaviour change techniques will be utilised to increase intervention effectiveness. These include barrier identification, problem solving, goal setting and action planning; social support; and instruction on how to perform a behaviour and behavioural practice.

### Table 1 Schedule of study measures

| Variable                                      | Instrument                                      | Timepoint |
|-----------------------------------------------|-------------------------------------------------|-----------|
| Inclusion/exclusion criteria                  | x                                               | Screening, Baseline, End of diet phase 1, End of washout, End of diet phase 2 |
| Informed consent                             | x                                               | Screening, Baseline, End of diet phase 1, End of washout, End of diet phase 2 |
| Demographic data and medical history         | Self-report and clinical records                | x         |
| Genotyping                                    | Venous blood sample                             | x         |
| Anthropometrics: weight, height, waist and hip circumference | Fasting venous blood samples                   | x         |
| Whole body composition                        | Bioelectrical impedance analysis                | x         |
| Cardio-metabolic measures: glucose, insulin, HbA1c, lipid profile and blood pressure | Fasting venous blood samples                   | x         |
| Liver function: LFTs, ferritin, FBC, CRP, lipid biomarkers | Fasting venous blood samples                   | x         |
| Liver steatosis: CAP                          | TE Fibroscan                                    | x         |
| Liver fibrosis: liver stiffness and PRO-C3   | TE Fibroscan                                    | x         |
| Patient-reported outcomes                    | EQ5D, CLDQ-NASH and NASH-CHECK                  | x         |
| Physical activity                             | Accelerometer                                   | x         |
| Dietary intake: dietary biomarkers, diet recall and MD questionnaire | Urine samples                                  | x         |
|                                               | INTAKE2                                         | x         |
|                                               | MEDAS                                           | x         |

CAP, controlled attenuation parameter; CLDQ-NASH, chronic liver disease questionnaire for non-alcoholic steatohepatitis; CRP, C-reactive protein; EQ-5D, euroqol five dimension scale; FBC, full blood count; HbA1c, glycated haemoglobin; LFTs, liver function tests; MD, Mediterranean diet; MEDAS, Mediterranean diet assessment score; PRO-C3, N-protease cleaved PIIINP neo-epitope; TE, transient elastography.
Diet 2 (control) will involve counselling participants to consume their habitual diet. During washout participants will be asked to return to their habitual diet. Participants will be asked to maintain baseline levels of physical activity and body weight (±3%) throughout the trial duration. The dietitian will contact participants by telephone midway through each diet phase to review progress, provide additional counselling and answer any queries.

Outcome assessment and process evaluation
The following criteria will be assessed.

The feasibility of recruitment and retention
The consent rate (the number of eligible participants who consent divided by the total number who are eligible and who are invited to participate), the recruitment rate (the number of participants recruited per month) and the retention rate (the number of participants who complete follow-up data collection divided by the total number randomised) will be assessed using a trial log between baseline and end of study.

The acceptability of the diets, instruments and procedures
Patient-reported outcome (PRO) data will be used to identify impact of diet treatments and trial procedures on quality of life using the PROs ‘EQ5D’, ‘CLDQ-NASH’ and ‘NASH-CHECK’.44–46 At 12 weeks, open-response questions will be used to capture participant perceptions of: (1) the randomisation procedure, (2) the acceptability of the MD intervention and (3) the components of the measurement protocol. These data will be recorded (online supplemental appendix 2), and thematic analyses performed.

Adherence to, and completion of, the diets and procedures
Participant adherence to trial procedures will be assessed by tracking the number of completed visits, and the completeness of data collection will be assessed using the trial log between baseline and 12 weeks.

Diet adherence will be assessed in self-report measures; Mediterranean diet assessment score (MEDAS) is based on a small number of foods measured in servings/day or servings/week. Scores range between 0 and 14, and can be categorised as low, moderate or high consumption (<5, 6–9 and >10 points, respectively).17 Dietary intake will be quantified using INTAKE24, an open-source computerised dietary recall system based on multiple-pass 24-hour recall.48–50 INTAKE24 data will be converted to MD scores and Dietary Inflammatory Index will be calculated.51

In addition, dietary biomarkers will be quantified in urine to provide objective measures of dietary intake, without self-report bias.51 Three spot urine samples will be collected at the beginning and end of each diet phase on non-consecutive days, including 1 weekend day, to provide estimates of habitual dietary intake. The three urine samples from each timepoint will be pooled and analysed using Ultra High-Performance Liquid Chromatography.52

Implementation fidelity and how practicable protocol processes are to deliver in a clinical setting
Data collection burden will be measured as the time taken to administer protocol processes. Participant processing time is the number of days from initial contact to enrolment. Both will be assessed using the trial log between baseline and end of study. To assess integrity and fidelity, a trial protocol checklist will be monitored with missing, incomplete or unreliable data recorded between baseline and end of study.

Preliminary exploratory data on liver fibrosis biomarkers and lipid biomarkers
In collaboration with partners in the EU IMI2-funded LITMUS biomarkers consortium (https://litmus-project.eu/), plasma will be analysed to characterise changes in the lipidome and metabolome to help elucidate mechanisms underlying specific changes in lipid metabolism. Plasma PRO-C3 concentration, as a marker of fibrogenesis, will be measured using competitive ELISAs.53

The data from this feasibility trial will be reported as descriptive summaries. Sample characteristics including age, gender, ethnicity, medical history and disease subclassification and severity will be presented. Although the trial is not powered to detect significant changes in clinical and lifestyle outcomes, key variables of interest (outlined in schedule of assessments) will be monitored and any preliminary changes reported. These data will determine the feasibility of testing components and enable the statistical power calculations for a subsequent RCT. The balance of the groups after randomisation will be explored. Descriptive statistics (mean, SD and counts (percentage)) will summarise continuous and categorical data as appropriate. No imputation of missing data will be undertaken.

Success criteria
The feasibility indicators are binary (successful or unsuccessful). ‘Successful’ would indicate the protocol is sufficiently robust to advance to a fully powered definitive RCT, while ‘unsuccessful’ indicates that protocol changes are required.54

1. The acceptability of diets, instruments and procedures.
2. Consent rate (25% of individuals consenting).
3. Recruitment rate (target 60 individuals/9 months, acceptable 45 individuals/9 months).
4. Retention rate (target 45 individuals/3 months, acceptable 36 individuals/3 months).
5. Participant adherence (75% completed visits/data collection).
6. Data collection burden (target >75% of individuals ≤1.5 hours, acceptable >75% of individuals <2 hours).
7. Participant processing time (mean time <14 days between initial contact to enrolment).
8. Trial protocol administration (<10% deviation from checklist).

Haigh L, et al. BMJ Open 2021;11:e045922. doi:10.1136/bmjopen-2020-045922
The main strength of this trial is the use of explicit feasibility and acceptability criteria as primary outcomes. Patient-reported outcome measures and open-response questions will be especially important to identify impact of diet treatments and trial procedures on quality of life and individuals’ perceptions of trial participation. In addition, the use of a cross-over design will facilitate more precise comparisons between intervention/control diets on a within-participant basis.57 This design is favoured in short-term trials of long-term conditions with intermediate outcomes.57 Nevertheless, a limitation of this design is the possibility of carryover effects from one experimental period to the next. We have addressed this issue by including a 4-week washout period. The required duration of washout period is influenced by the nature and duration of the intervention but, in nutritional cross-over studies, 2–4 weeks is often sufficient.58 59 This is confirmed by studies of metabolomics biomarkers in urine which show that these respond rapidly to dietary change.60 Importantly, we will evaluate the effectiveness of washout to return outcome variables to baseline. Additionally, participants will be supplied with intervention foods and counselled to return to habitual dietary intake during washout. Advice will be given to maintain baseline levels of physical activity and body weight (±3%) throughout. The intervention period (4 weeks) is relatively short and is unlikely to reveal the full effects of the dietary intervention on markers of liver health. Previous research has found that brief and short-term interventions effectively modified MD adoption and maintenance up to 12 months in non-Mediterranean countries39 61–63 and that, with appropriate support, dietary change can be sustained for up to 4 years in Spain.54 However, this study is designed, primarily, to provide information on the acceptability and feasibility of the study protocol. Finally, the MD intervention in this trial has been systematically developed and informed by research evidence and patient and public feedback.

This trial will assess the feasibility of conducting a genotype-driven RCT investigating the differential response to a MD intervention of patients according to genotype for the rs738409 (I148M) variant of PNPLA3. The findings of this trial will lay the foundation for a future definitive RCT by informing trial design and optimising the intervention diets, instruments and procedures. In the longer run, the outcomes of this research programme may lead to fewer patients with NAFLD who need intensified medical treatment, reducing cost burden, and premature mortality and morbidity.

Ethics and dissemination

Ethical approval was granted by East of Scotland Research Ethics Service REC I (19/ES/0112). NHS Research and Development approval was granted by the Newcastle upon Tyne Hospitals NHS Foundation Trust (R&D8985). This trial will be conducted to a high standard in accordance with the protocol, the principles of good clinical practice, relevant regulations, guidelines and with regard
to patient safety and welfare. The findings of this trial will be submitted for publication in peer-reviewed journals and presented at local, national and international meetings and conferences. A lay summary of results will be available for all study participants.

**Trial status**

The first participant was enroled on 11 February 2020 with recruitment expected to be completed by 31 March 2021. The recruitment period has been extended to mitigate the potential impact of COVID-19 on the research plans.

**Contributors**

LH, JCM and QMA conceived of the study. LH, SMcP, JCM and QMA contributed to design of the study. All authors revised the manuscript for important intellectual content with JCM and QMA giving final approval of the version to be published.

**Funding**

This research was funded by the NIHR Newcastle Biomedical Research Centre (BRC) (grant number BRC-1215-20001). The Newcastle Biomedical Research Centre (BRC) is a partnership between Newcastle Hospitals NHS Foundation Trust and Newcastle University, funded by the National Institute for Health Research (NIHR). QMA is a member of the LITMUS (Liver Investigation: Testing Marker Utility in Steatohepatitis) consortium funded by the Innovative Medicines Initiative (IM2) Programme of the European Union (Grant Agreement 777377).

**Disclaimer**

The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.

**Competing interests**

SMcP, Consultancy/speakers fees—AbbVie, Allergan, BMS, Gilead, Intercept, MSD, Novartis and Sequna. QMA: Research Grant Funded AbbVie, Allergan/Tobira, AstraZeneca, GlaxoSmithKline, Genzyme Bio, Novartis Pharma AG, Pfizer Ltd, Vertex. Active Research Collaborations (including research collaborations supported through the EU IM2 LITMUS Consortium*)—AbbVie, Antanos Medical*, Allergan/Tobira, AstraZeneca*, BMS*, Boehringer Ingelheim International GMBH*, EchoSENS*, EllaGard Gottingen Minipigs AS*, Eli Lilly & Company Ltd*, Exalenz Bioscience Ltd*, Genfit SA*, Glycopyrrole, Bio, GlaxoSmithKline*, Histoidex*, Intercept Pharma Europe Ltd*, IXagent Ltd*, Nordic Bioscience*, Novartis Pharma AG*, Novo Nordisk A/S*, One Way Liver Genomics SL*, Perspektum Diagnostics*, Pfizer Ltd*, Resoudan*, Sanofi-Aventis Deutschland GmbH*, SomaLogic Inc*, Takeda Pharmaceuticals International SA*, Consultancy 899Bio, Abbott Laboratories*, Acutis Medical, Alimune*, AstraZeneca, Axcella, Blade, BMS, BNN Cardio, Celgene, Cirus, CymaBay, EcoR1, E3Bio, Eli Lilly & Company Ltd*, Galmed, Genentech, Genfit SA, Gilead, Grunthal, Histoidex, Indalo, Imperial Innovations, Intercept Pharma Europe Ltd, Inventiva, iQVIA, Janssen, Madrical, Medimmune, Metacrine, NewGene*, NGMBio, North Sea Therapeutics, Novartis, Novo Nordisk A/S*, Pfizer Ltd, Poxel, ProSciento, Raptor Pharma, Servier, Terns, Viking Therapeutics. Speaker Abbott Laboratories, Allergan/Tobira, BMS, Clinical Care Options, Falk, Fishawack, Genfit SA, Gilead, Integritas Communications, Kenes, MedScape. Royalties Elsevier Ltd (Davidson's Principles & Practice of Medicine textbook).

**Patient consent for publication** Not required.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Supplemental material**

This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access**

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

**ORCID iD**

Laura Haigh http://orcid.org/0000-0002-9229-4127

**REFERENCES**

1. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology* 2016;64:73–84.

2. Younossi Z, Tacke F, Arrese M, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. *Hepatology* 2019;69:982–92.

3. Anstee QM, Tanzer G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. *Nat Rev Gastroenterol Hepatol* 2013;10:330–44.

4. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American gastroenterological association, American association for the study of liver diseases, and American college of gastroenterology. *Gastroenterology* 2012;142:592–609.

5. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. *J Hepatol* 2020;64:388–402.

6. Younossi Z, Anstee QM, Manetti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. *Nat Rev Gastroenterol Hepatol* 2018;15:11–20.

7. Anstee QM, Day CP. The genetics of nonalcoholic fatty liver disease: spotlight on PNPLA3 and TM6SF2. *Semin Liver Dis* 2015;35:270–90.

8. Liu Y-L, Fatman GL, Leathart JBS, et al. Carriage of the PNPLA3 rs738409 C→G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. *J Hepatol* 2014;61:75–81.

9. Stender S, Kozlitina J, Nordestgaard BG, et al. Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci. *Nat Genet* 2017;49:942–47.

10. Mann JP, Anstee QM. NAFLD: PNPLA3 and obesity: a synergistic relationship in NAFLD. *Nat Rev Gastroenterol Hepatol* 2017;14:506–7.

11. Romero-Gómez M, Zeibler-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. *J Hepatol* 2017;67:829–46.

12. Dong XC, PNPLA3-A potential therapeutic target for personalized treatment of chronic liver disease. *Front Med* 2019;6:304.

13. Gerber L, Otgonsuren M, Mishra A, et al. Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population-based study. *Aliment Pharmacol Ther* 2012;36:772–81.

14. Pingitore P, Rheims S. The role of PNPLA3 in health and disease. *Biochim Biophys Acta Mol Cell Biol Lipids* 2019;1864:900–6.

15. Basu Ray S. PNPLA3–I148M, a problem of plenty in non-alcoholic fatty liver disease. *Adipocyte* 2019;8:201–8.

16. Valenti L, Al-Serri A, Daly AK, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. *Hepatology* 2010;51:1209–17.

17. Anstee QM, Darlay R, Cockell S, et al. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. *J Hepatol* 2020;73:505–15.

18. Ryan MC, Itsiopoulos C, Thodis T, et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. *Adipocyte* 2013;2:138–43.

19. Katsagoni CN, Egkomiti A, Papageorghiou AT, et al. Mediterranean diet and liver health: a systematic review and meta-analysis of randomized controlled trials. *Hepatology* 2018;68:1741–54.

20. Salas-Salvadó J, Guasch-Ferré M, Lee C-H, et al. Protective effects of the Mediterranean diet on type 2 diabetes and metabolic syndrome. *J Nutr* 2015;145:9205–7.
25 Or dov aJM, Ferguson LR, Tai ES, et al. Personalised nutrition and health. BMJ 2018;361:j2173.
26 Dongiovanni P, Valent L A Nutrigenomic approach to non-alcoholic fatty liver disease. J Mol Sci 2017;18:1534.
27 Scorletti E, West AL, Bhatia L, et al. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: results from the welcome trial. J Hepatol 2015;63:1476–83.
28 Kalafati I-P, Borsa D, Dedoussis GVZ. The genetics of nonalcoholic fatty liver disease: role of diet as a modifying factor. Curr Nutr Rep 2014;3:23–32.
29 Shen J, Wong GL-H, Chan HL-Y, et al. PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2015;30:139–46.
30 Krwaczek M, Stachowka M, Wilczek P, et al. Reduction of caloric intake might override the prosteatogenic effects of the PNPLA3 p.I148M and TM6SF2 p.E167K variants in patients with fatty liver: ultrasound-based prospective study. Digestion 2016;93:139–48.
31 Davis JN, Lé K-A, Walker RW, et al. Increased hepatic fat in overweight Hispanic youth influenced by interaction between genetic variation in PNPLA3 and high dietary carbohydrate and sugar consumption. Am J Clin Nutr 2010;92:1522–7.
32 Sebastianova K, Kotronen A, Gastaldelli A, et al. Genetic variation in PNPLA3 (rs738409 SNP) confers sensitivity to weight loss-induced decrease in liver fat in humans. Am J Clin Nutr 2011;94:104–11.
33 Lancaster GA, Dodd S, Williamson PR. Design and analysis of pilot studies: recommendations for good practice. J Eval Clin Pract 2004;10:307–12.
34 Ensembl. variant: rs738409 SNP. 2020. Available: https://apr2020.archive.ensemble.org/Homo_sapiens/Variation/Population?db=core;r=22:43928347-43929347;v=rs738409;vdb=variation;v=88267060
35 Bach-Faig A, Berry EM, Laron D, et al. Mediterranean diet pyramid today. Science and cultural updates. Public Health Nutr 2011;14:2276–84.
36 Anania C, Perla FM, Olivero F, et al. Mediterranean diet and nonalcoholic fatty liver disease. World J Gastroenterol 2018;24:2083–94.
37 Tong TYN, Imamura F, Monsivais P, et al. Dietary cost associated with adherence to the Mediterranean diet and its variation by socio-economic factors in the UK Fenland study. Br J Nutr 2018;119:685–94.
38 Mills S, Adams J, Wrieden W, et al. Sociodemographic characteristics and frequency of consuming home-cooked meals and meals from out-of-home sources: cross-sectional analysis of a population-based cohort study. Public Health Nutr 2018;21:2255–66.
39 Haigh L, Bremmer S, Houghton D, et al. Barriers and facilitators to Mediterranean diet adoption by patients with nonalcoholic fatty liver disease in northern Europe. Clin Gastroenterol Hepatol 2019;17:1364–71.
40 The British Dietetic Association. Model and process for nutrition and dietetic practice. 2016.
41 Lara J, Evans EH, O’Brien N, et al. Association of behaviour change techniques with effectiveness of dietary interventions among adults of retirement age: a systematic review and meta-analysis of randomised controlled trials. BMC Med 2014;12:177.
42 Craddock KA, O’Laughlin G, Finucane FM, et al. Behaviour change techniques targeting both diet and physical activity in type 2 diabetes: a systematic review and meta-analysis. Int J Behav Nutr Phys Act 2017;14:18.
43 Michie S, Richardson M, Johnston M, et al. The behavior change technique taxonomy (v1) of 93 hierarchically clustered techniques: building an international consensus for the reporting of behavior change interventions. Ann Behav Med 2013;46:81–95.
44 Devlin NJ, Brooks R, EQ-SD and the EuroQol group: past, present and future. Appl Health Econ Health Policy 2017;15:127–37.
45 Younossi ZM, Stepanova M, Younossi I, et al. Validation of chronic liver disease questionnaire for nonalcoholic steatohepatitis in patients with biopsy-proven nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2019;17:2093–100.
46 Doward LC, Balp M-M, Twiss J, et al. Development of a patient-reported outcome measure for non-alcoholic steatohepatitis (NASH-CLEARDI): results of a qualitative study. Patient 2020; doi:10.1007/s40271-020-00485-w. [Epub ahead of print: 18 Dec 2020].
47 Martínez-González MA, García-Arellano A, Toledo E, et al. A 14-item Mediterranean diet assessment tool and obesity indexes among high-risk subsidized: the PREDIMED randomised trial. Nutr Res 2012;7:e43134.
48 Simpson E, Bradley J, Poliakiv I, et al. Iterative development of an online dietary recall tool: INTAKE24, Nutrients 2017;9: doi:10.3390/nu9020118. [Epub ahead of print: 09 Feb 2017].
49 Foster E, Lee C, Imamura F, et al. Validity and reliability of an online self-report 24-h dietary recall method (INTAKE24): a doubly labelled water study and repeated-measures analysis. J Nutr Sci 2019;8:e29.
50 Shivappa N, Steck SE, Hurley TG, et al. Designing and developing a literature-derived, population-based dietary inflammatory index. Public Health Nutr 2016;19:3165–80.
51 Lloyd AJ, Wilson T, Willis ND, et al. Developing community-based urine sampling methods to deploy biomarker technology for the assessment of dietary exposure. Public Health Nutr 2020;23:3081–92.
52 Lloyd AJ, Willis ND, Wilson T, et al. Developing a food exposure and urine sampling strategy for dietary exposure biomarker validation in free-living individuals. Mol Nutr Food Res 2019;63:190062.
53 Boyle M, Tinakos D, Schattenberg JM, et al. Performance of the pro-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease. JHEP Rep 2019;1:168–78.
54 Eldridge SM, Chan CL, Campbell MJ, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ 2016;355:i5239.
55 Sánchez M, Boqué N, Del Bas JM, et al. Mediterranean diet and Multi-Ingredient-Based interventions for the management of non-alcoholic fatty liver disease. Nutrients 2017;9:1052.
56 Penn L, Boeijing H, Boushey CJ, et al. Assessment of dietary intake: NuGO symposium report. Genes Nutr 2010;5:205–13.
57 Younge JO, Kouvonen-Pasmo M, Aikak-Poli R, et al. Randomised controlled crossover study of monitoring human dietary exposure by metabolite fingerprinting of urine samples. Metabolomics 2011;7:469–84.
58 Harris JE, Raynor HA. Crossover designs in nutrition and dietetics research. J Acad Nutr Diet 2017;117:1023–30.
59 Keogh GF, Cooper GJS, Mulvey TB, et al. Randomized controlled crossover study of the effect of a highly beta-glucan-enriched barley on cardiovascular disease risk factors in mildly hypercholesterolemic men. Am J Clin Nutr 2003;78:711–8.
60 Favé G, Beckmann M, Lloyd AJ, et al. Development and validation of a standardized protocol to monitor human dietary exposure by metabolite fingerprinting of urine samples. Metabolomics 2011;7:469–84.
61 Logan KJ, Woodside JV, Young IS, et al. Adoption and adherence of a Mediterranean diet in patients with coronary heart disease from a northern European population: a pilot randomised trial of different methods of delivering Mediterranean diet advice. J Hum Nutr Diet 2010;23:30–7.
62 Lara J, Turbett E, Mckevic A, et al. The Mediterranean diet among British older adults: its understanding, acceptability and the feasibility of a randomised brief intervention with two levels of dietary advice. Maternal 2015;82:387–93.
63 Berendsen AAM, van de Rest O, Feskens EJM, et al. Changes in dietary intake and adherence to the NU-AGE diet following a one-year dietary intervention among European older Adults-Results of the NU-AGE randomized trial. Nutrients 2018;10. doi:10.3390/ nu10121905. [Epub ahead of print: 04 Dec 2018].
64 Downer MK, Gea A, Stampfer M, et al. Predictors of short- and long-term adherence with a Mediterranean-type diet intervention: the PREMIDMED randomized trial. Int J Behav Nutr Phys Act 2016;13:67.